Clinical trialPhase 2Recruiting
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 8 November 2023
- Expected end
- December 2028
- Enrollment
- 25 participants
- Sites
- 2
- Primary outcomes
- Change in Immune response rate as assessed by density of intratumoral granzyme B+ CD137+ T cells; Pathologic Response Rate as assessed by number of patients with a grade 0-2 pathologic response
- Sponsor
- Other
- Results posted
- No
- Last update
- 7 October 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to evaluate the safety and clinical activity of tislelizumab (an anti-PD-1 antibody) in combination with SX-682 (a CXCR1/2 inhibitor) in subjects with newly diagnosed and surgically resectable pancreatic adenocarcinoma.